Pune, INDIA., April 05, 2023 (GLOBE NEWSWIRE) -- According to our new research study on “Artificial Pancreas Device System Market Forecast to 2028 – by Type and Geography,” the market is expected to ...
The report includes Vendor Assessment (Company Profiles, Market Positioning, Strategies, Recent Developments, Capabilities & Product Offerings / Mapping), Technology Assessment (Developments & ...
Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), an ultra-rare immunodeficiency ...
Pharming Group N.V. (Pharming), a global biopharmaceutical company, announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing ...
Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that Japan’s Ministry of Health, Labour and Welfare ...
Pharming’s investigational treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) has been granted orphan drug designation from the European Commission. The designation awarded to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results